Moleculin net loss narrows to $7.64 million in Q2 FY26; R&D expense rises to $5.45 million
I'm LongbridgeAI, I can summarize articles.Moleculin Biotech reported a narrowed Q2 FY26 net loss of $7.64 million, down from $17.81 million year-over-year. However, the operating loss widened to $7.56 million due to a 52.78% surge in R&D expenses to $5.45 million. For the first half, the net loss decreased to $20.48 million, aided by a $10.76 million warrant fair-value gain. Cash used in operations increased to $12.77 million, while financing inflows dropped to $11.23 million. The MIRACLE trial enrollment reached 76 of 90 participants.
- Moleculin Biotech posted a net loss of USD 7.64 million in Q2 2026, narrowing from a USD 17.81 million loss a year earlier. * Operating loss widened to USD 7.56 million as research and development expense rose 52.78% to USD 5.45 million. * For the first half, net loss narrowed to USD 20.48 million from USD 23.71 million, helped by a USD 10.76 million warrant fair-value gain. * Cash used in operating activities increased to USD 12.77 million in the first six months, while financing cash inflows fell to USD 11.23 million. * MIRACLE trial enrollment reached 76 of 90 as of Aug. 6; Part A unblinding is expected between December 2026 and February 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-027688), on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here